Literature DB >> 31196235

Exploring demoralization in end-of-life cancer patients: Prevalence, latent dimensions, and associations with other psychosocial variables.

Andrea Bovero1, Rossana Botto1, Beatrice Adriano1, Marta Opezzo1, Valentina Tesio2, Riccardo Torta1.   

Abstract

OBJECTIVE: Demoralization is an existential distress syndrome that consists of an incapacity of coping, helplessness, hopelessness, loss of meaning and purpose, and impaired self-esteem. It can affect cancer patients, and the Demoralization Scale is a valid instrument to assess it. The present study aimed to investigate the prevalence of demoralization in end-of-life cancer patients and its associations with the medical and psychosocial variables. In addition, the latent dimensions of demoralization emerging in this distinctive population were explored.
METHOD: The study is cross-sectional. The sample consisted of 235 end-of-life cancer patients with a Karnofsky performance status (KPS) lower than 50 and a life expectancy of a few weeks. For each patient, personal and medical data was gathered by a palliative physician and a set of validated rating scales, assessing demoralization, anxiety, depression, physical symptoms, pain, spiritual well-being, and dignity, was administered by a psychologist during the first consultation. RESULT: Sixty-four participants (27.2%) had low demoralization, 50.2% (n = 118) had medium demoralization, and 22.6% (n = 53) had high demoralization. Factor analysis evidenced a five-factor solution that identified the following demoralization factors: Emotional Distress and Inability to Cope, Loss of Purpose and Meaning, Worthlessness, Sense of Failure, and Dysphoria. All the considered variables were associated with demoralization, except for pain, nausea, breathing problems, and sociodemographic and clinical variables. SIGNIFICANCE OF
RESULTS: End-of-life cancer patients showed higher levels of demoralization than has been reported in other studies with advanced cancer. These data could suggest that demoralization could increase in proximity to death and with impaired clinical condition. In particular, the five demoralization dimensions that emerged could represent the typical concerns around which the syndrome evolves in end-of-life cancer patients. Finally, spiritual well-being could play a protective role with respect to demoralization.

Entities:  

Keywords:  Cancer; Demoralization; End-of-life patients; Palliative care

Mesh:

Year:  2019        PMID: 31196235     DOI: 10.1017/S1478951519000191

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  4 in total

1.  A systematic scoping review on patients' perceptions of dignity.

Authors:  Keith Zi Yuan Chua; Elaine Li Ying Quah; Yun Xue Lim; Chloe Keyi Goh; Jieyu Lim; Darius Wei Jun Wan; Simone Meiqi Ong; Chi Sum Chong; Kennan Zhi Guang Yeo; Laura Shih Hui Goh; Ray Meng See; Alexia Sze Inn Lee; Yun Ting Ong; Min Chiam; Eng Koon Ong; Jamie Xuelian Zhou; Crystal Lim; Simon Yew Kuang Ong; Lalit Krishna
Journal:  BMC Palliat Care       Date:  2022-07-04       Impact factor: 3.113

2.  Demoralization level fluctuated at various time frame of radiotherapy for patients with different cancers: a longitudinal observational study.

Authors:  Pei-Ling Tang; Huey-Shyan Lin; Hsiu-Hung Wang; Li-Yu Hu; Fan-Hao Chou
Journal:  BMC Palliat Care       Date:  2022-08-10       Impact factor: 3.113

3.  Demoralization and Its Association with Quality of Life, Sleep Quality, Spiritual Interests, and Suicide Risk in Breast Cancer Inpatients: A Cross-Sectional Study.

Authors:  Ting-Gang Chang; Chih-Chiang Hung; Pei-Ching Huang; Chiann-Yi Hsu; Ting-Ting Yen
Journal:  Int J Environ Res Public Health       Date:  2022-10-06       Impact factor: 4.614

4.  Personality matters: relationship between personality characteristics, spirituality, demoralization, and perceived quality of life in a sample of end-of-life cancer patients.

Authors:  Ada Ghiggia; Vanni Pierotti; Valentina Tesio; Andrea Bovero
Journal:  Support Care Cancer       Date:  2021-06-24       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.